E
Personalis, Inc. PSNL
$1.54 -$0.06-3.75%
Recommendation
Sell
Prev Close
$1.29
Volume
356,039
Avg Vol (90D)
434,552
Market Cap
$66.06M
Dividend & Yield
--
52-Week Range
$0.8906 - $2.67
P/E (TTM)
--
EPS (TTM)
-$2.26
My Lists My Alerts
Report
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Lake Street Capital Begins Coverage on Personalis (NASDAQ:PSNL)
5/4/2024 - Ticker Report
Personalis initiated with bullish view at Lake Street, here's why
4/30/2024 - The Fly
Personalis to Announce First Quarter 2024 Financial Results
4/24/2024 - Business Wire
Personalis (NASDAQ:PSNL) vs. Biodesix (NASDAQ:BDSX) Critical Survey
4/20/2024 - Zolmax
Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower
4/19/2024 - Simply Wall St
Needham & Company LLC Reaffirms Buy Rating for Personalis (NASDAQ:PSNL)
4/14/2024 - Zolmax
Personalis (NASDAQ:PSNL) Given Buy Rating at Needham & Company LLC
4/11/2024 - Ticker Report
Buy Rating Affirmed for Personalis, Inc. on Strong Growth Prospects and Innovative Cancer Assays
4/11/2024 - TipRanks Financial Blog
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
3/28/2024 - Business Wire
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
3/28/2024 - Business Wire
Personalis Announces Publication Validating NeXT Personal Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
3/26/2024 - Business Wire
Elon Musk is impressed with Cathie Wood's latest research
3/22/2024 - TheStreet.com
Cathie Wood's ARK Investment bought 142K shares of Personalis today
3/21/2024 - The Fly
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/19/2024 - Business Wire
Green Alpha Advisors LLC Lowers Stake in Personalis, Inc. (NASDAQ:PSNL)
3/15/2024 - Ticker Report
Buy Rating Affirmed: Personalis's Strategic Advances and Financial Health Signal Promising Growth in 2024
3/4/2024 - TipRanks Financial Blog
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story
3/2/2024 - Simply Wall St
Acadian Asset Management LLC Has $452,000 Stock Position in Personalis, Inc. (NASDAQ:PSNL)
3/2/2024 - Zolmax
Personalis (NASDAQ:PSNL) PT Raised to $3.50
3/2/2024 - Zolmax
Needham & Company LLC Boosts Personalis (NASDAQ:PSNL) Price Target to $3.50
2/29/2024 - Ticker Report
Q4 2023 Personalis Inc Earnings Call Transcript
2/29/2024 - GuruFocus
Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript
2/29/2024 - SeekingAlpha
Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript
2/29/2024 - Seeking Alpha: Transcripts
Personalis sees FY24 revene $73M-$75M, consensus $75.0M
2/28/2024 - The Fly
Personalis sees Q1 revenue $18M-$19M, consensus $19.7M
2/28/2024 - The Fly
Income Statement
Total Revenue (TTM)
$73.48M
EBITDA (TTM)
-$85.00M
EBIT (TTM)
-$96.29M
Net Income (TTM)
-$108.30M
Balance Sheet
Total Assets (Q)
$225.10M
Total Debt (Q)
$48.96M
Total Liabilities (Q)
$95.66M
Book Value Per Share (Q)
$2.56
Cash Flow
Cash from Operations (TTM)
-$56.26M
Cash from Investing (TTM)
$13.10M
Cash from Financing (TTM)
$11.03M
Net Change in Cash (TTM)
-$32.14M
Filings
Filing Date
Wednesday, February 28, 2024
Period Date
Sunday, December 31, 2023
Next Filing
Beginning of May (est)
Price History
Loading...
Beta
1.47
7-Day Total Return
0.83%
30-Day Total Return
-23.42%
60-Day Total Return
-9.70%
90-Day Total Return
-19.87%
Year to Date Total Return
-40.69%
1-Year Total Return
-41.55%
2-Year Total Return
-78.96%
3-Year Total Return
-95.01%
5-Year Total Return
--
52-week Low
Nov 10, 2023 - $0.8906
52-week High
Apr 20, 2023 - $2.67
Valuation
Market Cap
$66.06M - Micro Cap
Enterprise Value
$843.68K
Price/Sales (TTM)
0.87
Price/Book (Q)
0.50
Dividends and Shares
Shares Outstanding
49.60M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.personalis.com
Phone Number
650 752 1300
Address
6600 Dumbarton Circle
Fremont, CA 94555
Country
United States
Year Founded
2011
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical... more
NASDAQ 05/03/2024 4:00PM Eastern Quotes delayed
Weiss Ratings